• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CPH 1.25% 20.3¢

CRESO PHARMA LIMITED - Corporate Spotlight

Creso Pharma (ASX:CPH) is leading the medicinal cannabis space focusing on low THC... Creso Pharma (ASX:CPH) is leading the medicinal cannabis space focusing on low THC products for pain relief and relaxation. Creso has secured the services of Canopy Growth founder, Bruce Linton as a strategic advisor for the business. Watch this space.More

Corporate Spotlight

Creso Pharma (ASX:CPH) is leading the medicinal cannabis space focusing on low THC products for pain relief and relaxation. Creso has secured the services of Canopy Growth founder, Bruce Linton as a strategic advisor for the business. Watch this space.
View the full Corporate Spotlight arrow Created with Sketch.

Creso Pharma to acquire Canadian psychedelics play

CPH APPOINTS DIRECTOR OF US DEVELOPMENT

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) appoints Director of U.S. development, as New York State legalises recreational cannabis

Health Care

ASX:CPH 
Creso Pharma (ASX:CPH) appoints Director of U.S. development, as New York State legalises recreational cannabis

  • Creso Pharma (CPH) has appointed leading cannabis executive John Griese as Director of U.S. business development
  • The appointment follows the recent legislation in New York State legalising recreational marijuana
  • John has nearly 30 years of experience and has previously worked for Creso, as well as large multinational companies such as Nestle and PepsiCo
  • John will focus on New York, Vermont and other states to delineate a strategy for Creso Pharma to begin delivering products in the U.S.
  • Interestingly, New York State is expected to become one of the largest recreational markets in the U.S., valued at US$4.2 billion (A$5.5 billion)
  • On the market this afternoon, Creso is down 4.76 per cent and is trading at 20 cents per share

Creso Pharma (CPH) has appointed leading cannabis executive John Griese as Director of U.S. business development.

This follows the recent legislation in New York State legalising recreational marijuana.


John brings nearly 30 years of experience to Creso and has previously worked with large multinational companies such as Nestle and PepsiCo.


Additionally, he also has considerable experience in the cannabis sector through previous roles with Creso Pharma, Blooms Farms and his most recent position as Chief Operating Officer at Supreme Cannabis Company.


"We are very excited to welcome John back to Creso and Board and management are very confident that his new role will unlock a number of potential opportunities for the Company throughout the U.S," Chairman Adam Blumenthal said.


"The recent legislative push in New York State highlights the ongoing shift towards the federal legalisation of recreational cannabis and John’s appointment shows Creso Pharma’s commitment to establishing a strong foothold in-country to unlock value for our shareholders," he added.


John will focus on New York, Vermont and other states to delineate a strategy for Creso Pharma to begin delivering products in the U.S.


Interestingly, New York State is expected to become one of the largest recreational markets in the U.S., valued at US$4.2 billion (A$5.5 billion).


Creso's ability to export its cannabis products into the U.S. will remain subject to the federal legislation of cannabis. According to the company, having John commence supply, sale, distribution and partnership agreements now, pending federal legalisation, will provide the company with an opportunity to be a first mover in this large market.


"Once federal legalisation occurs, Creso expects to have made inroads into the U.S. via these partnerships and agreements, which will provide speed to market and allow the company to cater to the largest consumer market of cannabis in the world in a much more seamless manner," the company explained.


Speaking in his new role John said the North American market provides a significant opportunity for Creso Pharma.

"I look forward to working with the company to assist in growing its foothold in the U.S," John concluded.

On the market this afternoon, Creso is down 4.76 per cent and is trading at 20 cents per share at 12:45 pm AEST.


To read the full article on The Market Herald click here.

CPH LAUNCHES 3 CBD BASED TEAS

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) launches three CBD-based teas

Health Care

ASX:CPH   
Creso Pharma (ASX:CPH) - Co Founder, Boaz Wachtel (left) - The Market Herald
Co Founder, Boaz Wachtel (left)

  • Creso Pharma (CPH) has launched three new CBD-based tea products under its cannaQIX brand
  • These products are now available in Switzerland with additional European markets expected in the near-term
  • The company will also be looking to sell its products in Germany following a reversal of charges against hemp sellers in the country
  • These CBD-based teas include cannaQIX tea, cannaQIX NITE tea and cannaQIX Immunity tea, and they aim to reduce stress, enable better sleep and optimise well-being
  • Creso will use the technology that helped with the manufacturing of these teas for its flagship lozenge products
  • Creso is up 2.5 per cent on the market and shares are trading at 20.5 cents

Creso Pharma (CPH) has launched three new CBD-based tea products under its cannaQIX brand.


These products are now available in Switzerland with additional European markets expected in the near-term.


Following a recent decision by the German Federal Court of Justice to reverse charges against hemp tea sellers, Creso will be looking to launch its teas in Germany.


Upon a successful launch of its products in Switzerland and Germany, Creso will aim to expand its reach into other European countries.


These CBD-based teas include cannaQIX tea, cannaQIX NITE tea and cannaQIX Immunity tea.




The cannaQIX tea is designed to help the management of stress, the cannaQIX NITE tea is to be consumed at night for a better sleep, while cannaQIX immunity tea optimises well-being.


Creso will use the technology that helped with the manufacturing of these teas for its flagship lozenge products.


"We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma," Commercial and Development Director Dr Gian Trepp said.


"The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX lozenges," he added.


Creso is up 2.5 per cent on the market and shares are trading at 20.5 cents at 3:17 pm AEDT.


To read the full article on The Market Herald click here. 

CRESO EYES MEDICINAL PSYCHEDELICS MARKET

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) eyes medicinal psychedelics market

Health Care

ASX:CPH   


  • Medicinal cannabis player Creso Pharma (CPH) is set to acquire Halucenex Life Sciences, a Canadian psychedelics treatment company
  • Under the proposed buy, Creso will purchase the life sciences developer for a mixture of cash and shares in its bid to enter the emerging medicinal psychedelics market 
  • Halucenex operates as a medical treatment facility and controlled substances laboratory in Nova Scotia and is currently awaiting licensing to possess and conduct research with psilocybin, LSD and MDMA
  • Creso has described the buy as "transformational" and affirms public policy towards psychedelics is rapidly shifting
  • Following today's deal, shares in Creso Pharma have opened Monday's trading session up 4.76 per cent trading at 21 cents each



Medicinal cannabis player Creso Pharma (CPH) is set to acquire Halucenex Life Sciences, a Canadian psychedelics treatment company.


Creso has signed an agreement to buy the life sciences developer, which is geared towards researching and developing psychedelic treatments for mental illnesses such as post-traumatic stress disorder (PTSD) and depression. 


The proposed buy has been described as "transformational" by Creso and is hoped to grant the company entry to the emerging psychedelics medicines market, which it estimates to be worth up to US$100 billion (roughly A$128.5 billion).


According to CPH, it's a move that could also see the debut of the first 100 per cent-owned psychedelic medicines company listed on the ASX, should the buy go ahead. 


Halucenex operates a medical treatment facility in Nova Scotia, Canada, which comes equipped with a controlled substances laboratory and 18 treatment rooms for psychedelic-assisted psychotherapy.


Upon receipt of its Controlled Drugs and Substances Dealer's licence, Halucenex will be permitted to possess and conduct research and development on psychedelic molecules including psilocybin, LSD and MDMA.


Halucenex has emphasised a particular focus on synthetic psilocybin — the active ingredient in magic mushrooms — which is tipped to have considerable evidence-based mental health benefits, according to CPH.


Consideration for the acquisition will be a mixture of both cash and shares. Creso will need to front $500,000 in cash and issue 29.2 million CPH shares under the deal, with an extra 17.5 million CPH shares to be issued once the licence is granted.


Commenting on the deal, Creso’s Strategic Advisor Bruce Linton said public policy towards psychedelics is rapidly shifting. 


"We are witnessing a massive regulatory wave which will change the way that mental health disorders are treated," he commented. 


"Creso’s decision to enter the psychedelic space allow it to capitalise on its strong global partnerships, and its team’s expertise in the development of new pharmaceutical products, to accelerate commercialisation of one of the world’s first psychedelic inspired medicines," he concluded. 


Following today's deal, shares in Creso Pharma have opened Monday's trading session up 4.76 per cent trading at 21 cents each at 11:01 am AEDT.


Read the full article on The Market Herald here.

CPH SET TO BENEFIT FROM NEW AUS APPROVAL

arrow-down-2 Created with Sketch.


Creso Pharma (ASX:CPH) set to benefit from over-the-counter CBD sales

Health Care

ASX:CPH   
Botanix set to raise $40M for cannabinoid skincare medicine

  • Medicinal cannabis company Creso Pharma (CPH) is set to benefit from a new development in the Australian cannabidiol (CBD) industry
  • From February 1 2021, customers may buy low-dose CBD products from over-the-counter in pharmacies without needing a prescription
  • This development follows the Therapeutic Goods Administration's final decision to down-schedule low-dose CBD from Schedule 4 to Schedule 3
  • Significantly, this unlocks a market that is estimated to exceed $200 million per annum
  • Non-Executive Chairman Adam Blumenthal says the decision provides the company with another exciting growth opportunity and potential revenue stream



Creso Pharma (CPH) is set to benefit from over-the-counter sales of low-dose cannabidiol (CBD) products in Australian pharmacies from February 1 2021.


Effective immediately, CBD products that contain no more than 150 milligrams per day, can be sold by a pharmacist to adults without needing a prescription.


This development in the Australian medicinal CBD industry follows the Therapeutic Goods Administration's (TGA) final decision to down-schedule low dose CBD from Schedule 4 to Schedule 3. 


Schedule 4 meant patients could be given low-dose CBD through a prescription only. However, Schedule 3 allows people to purchase these products over the counter.


Significantly, the decision unlocks a market that is estimated to exceed $200 million per annum.


"The TGA’s decision to allow the sale of low–dose CBD products to consumers without a prescription provides Creso Pharma with another exciting opportunity to grow in Australia and another potential revenue stream for the company," Non-Executive Chairman Adam Blumenthal said.


Creso Pharma has a portfolio of CBD products that are actively sold in several countries around the world. Its flagship CannaQIX 50 product is already available in Australia through prescription, under the LozaCan brand.


The CannaQIX range of CBD oil products is aimed improving stress management and supporting mental health and nervous functions.


Another advantage CPH has under its belt is the heads of agreement signed in December with sustainable health and lifestyle brand supplier Martin & Pleasance.


Martin & Pleasance has an in-house regulatory team as well as an extensive workforce that services over 4000 pharmacies in Australia and New Zealand, as well as online channels, grocery and practitioner suppliers.


The companies are now collaborating on ways to progress regulatory pathways for low-dose CBD products and define business cases. This will allow Creso to grow its footprint with Australian pharmacies.


"We will continue to work with Martin & Pleasance to define the specific regulatory pathway for our product in the Australian market and look forward to proving its superiority through the ARTG registration process," Adam concluded.


Read the full article on The Market Herald here.

CPH AIMS HIGH IN CANADA CANNABIS MARKET

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) aims high in Canadian cannabis market

Consumer Discretionary, Health Care

ASX:cph

·Creso Pharma (CPH) is making further inroads into the Canadian cannabis market with its products being added to the Ontario Cannabis Store's stock list

·Creso's subsidiary Mernova has been selected as an official supplier to the Ontario Cannabis Retail Corporation (OCRC), acting as the Ontario Cannabis Store (OCS)

·The monopoly provider services Canada's largest recreational cannabis market through both brick-and-mortar shopfronts and an online store

·Monthly sales in September alone totalled almost C$80 million (around A$81 million), accounting for over 30 per cent of Canada's total consumption

·Under the agreement, Mernova will supply its Ritual Green range of artisanal cannabis strains to the OCS, with first orders expected imminently

·While volume commitments are still yet to be finalised, Creso and Mernova anticipate strong sales growth in the near-term

·Creso Pharma closed Wednesday's session 6.38 per cent lower at 22 cents

Creso Pharma (CPH) is making further inroads into the Canadian cannabis market with its products being added to the Ontario Cannabis Store's stock list.

Read the full article on The Market Herald



Creso Pharma (ASX:CPH) and the US Bill

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) shares up 30pc amid speculation on U.S. cannabis bill

Health Care

ASX:CPH    MCAP $68.84M

Creso Pharma (ASX:CPH) shares up 30pc amid speculation on U.S. cannabis bill

·Creso Pharma's (CPH) shares are up 30 per cent as the U.S. House of Representatives passes a bill to decriminalise cannabis at a national level 

·The House passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis as an illegal substance from the US Controlled Substances Act

·The bill made it through the lower chamber 228 to 164 on December 4 but will need to pass in the senate to become federal law

·While the bill is not guaranteed to pass in the senate, it marks a significant milestone for the cannabis industry 

·Creso's shares are up a comfortable 30 per cent, trading at 13 cents

Creso Pharma's (CPH) shares are up 30 per cent as the U.S. House of Representatives passes a bill to decriminalise cannabis at a national level.

The House passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis as an illegal substance from the US Controlled Substances Act.

MORE aims to effectively decriminalise marijuana on a national level by erasing certain federal convictions.

Read the full article on The Market Herald 


TGA'S CANNABIDOL DECISION COMING SOON

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

Health Care

ASX:CPH    MCAP $21.34M

Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

Source: Creso Pharma

·Creso Pharma (CPH) is expecting Therapeutic Goods Administration's (TGA) decision in late December that will be a game-changer for cannabidiol products 

·TGA is making a decision that could see CBD products sold over the counter at pharmacies without the need of a prescription

·This decision could open a new large market potential for Creso, with the Australian market estimated to be worth around $200 million every year

·On the market this afternoon, Creso is up 6.45 per cent and is trading at 3.3 cents per share

Creso Pharma (CPH) says the Therapeutic Goods Administration (TGA) decision, on a major regulatory change for cannabidiol products, is expected next month. 

In September, TGA recommended that CBD products be downscaled from schedule four to schedule three medicines in Australia. This would allow Australian consumers to purchase CBD products over the counter without the need of a prescription. 

The potential down scheduling of CBD products in Australia opens the doors for Creso's CBD and hemp products. Currently, it is estimated the Australian market is worth over $200 million per annum and growing. 

Creso's cannaQIX 50 is sold in Australia as a medicinal cannabis product under the name LozaCan. The company has created a further range of CBD and hemp oil products, which it expects to sell in Australia if the TGA decision is positive. 

"The potential down scheduling of CBD is a major development for the broader market and provides Creso Pharma with a number of opportunities and potential new sales channels," Non-Executive Chairman Adam Blumenthal said. 

"Australia has always been considered an important market in our growth strategy. Ahead of the TGA’s final decision, the Board and management have been exploring initiatives which will allow us to capture a large market share in Australia and unlock value for our shareholders," he added.

Read the full article on The Market Herald


CPH LOCKS IN ANOTHER MERNOVA PURCHASE

arrow-down-2 Created with Sketch.

Creso Pharma (ASX:CPH) locks in another Mernova purchase

Health Care

ASX:CPH    MCAP $19.27M 
Co founder, CEO & Executive Director, Dr Miri Halperin Wernli
Sourced: Star Investing


  • Creso Pharma (CPH) has locked its third purchase order from the Nova Scotia Liquor Corporation (NSLC) in four weeks
  • The order was received by Creso's Canadian subsidiary, Mernova Medicinal, for its new Mimosa product
  • The Mimosa brand is designed to target consumers who want premium cannabis products at a reasonable price
  • Creso says it has already booked around $340,000 in revenue from NSLC orders in the past month alone
    Moreover, Mernova Managing Director Jack Yu says the company is expecting further orders to be finalised in the near term
    Cannabis specialist Creso Pharma (CPH) has locked its third purchase order from the Nova Scotia Liquor Corporation (NSLC) in four weeks.


    The order was received by Creso's Canadian subsidiary, Mernova Medicinal, for its new Mimosa product, which part of its Ritual Green brand. The Mimosa strain is made up of between 15 per cent and 20 per cent tetrahydrocannabinol (THC) and less than 1 per cent cannabidiol (CBD).


The NSLC has ordered 20 cases of Mimosa, which is listed at C$35 (roughly A$37) per 3.5 grams. According to Creso, this is a competitive price point that unlocks a broad market opportunity for the company. 


The Mimosa brand is designed to target consumers who want premium quality cannabis products at a reasonable price. 

Over the past four weeks, NSLC has also placed purchase orders for Creso's premium strains, HPG13 and Lemon Haze. Both of these products comprise between 20 per cent and 25 per cent THC and less than 1 per cent CBD. 


Mernova's Ritual Green products are sold through the NSLC's stores and e-commerce platform. Moreover, Creso said it has made roughly C$320,000 (around A$340,000) in revenue from NSLC in the last month alone. 


Mernova Managing Director Jack Yu said today's purchase order from NSLC further validates the success of the Ritual Green product launch. 


"Our products continue to garner very positive feedback from customers and we are confident that the Mimosa strain will unlock a large portion of the market that we can capitalise on in the near term," Jack said. 


"We look forward to updating shareholders on progress in Nova Scotia, additional strain launched under the Ritual Green product range, and further orders to be finalised in the near-term," he said. 


Read the full article on The Market Herald

VIDEO & MEDIA

arrow-down-2 Created with Sketch.



Creso Pharma (ASX:CPH) secures commitments to raise nearly $9M



CPH Secure High Profile Cannabis Exec

arrow-down-2 Created with Sketch.

Creso Pharma secures high profile cannabis executive as strategic advisor

  

Aussie Cannabis start-up Creso Pharma (ASX:CPH) has revealed it has secured the services of the Canopy Growth founder Bruce Linton has a strategic advisor for the business.

Bruce Linton turned Canopy Growth from 1 of 1000 cannabis start-ups jostling for market position in the early 2010’s to a NYSE and TSX listed monster with a market cap that once peaked at an eye-watering US$ 15 billion.

Bruce will join Creso Pharma’s Swiss subsidiary Creso Pharma Switzerland GMBH, where he will assume the role of strategic advisor to the business.

Bruce Linton is something of a unique cannabis executive, in that he has regularly stated he doesn’t see the future of cannabis in the high THC CBD market that so many others are aggressively pursuing. 

This probably explains why he elected to join on with Creso, who have been developing low THC cannabinoids aimed at reducing stress, rather than high THC cannabinoids used primarily for recreation in the North American market. 
 

THE BACKGROUND ON BRUCE

Bruce’s true strength is that markets tend to believe him when he talks about cannabis, and investors back him when he makes plays.

When he was at Canopy, he went to the market for finance 16 times, and secured the business a massive $US5 billion from the market in cap raisings.

He also guided Canopy through a merger in 2015 with another Canadian cannabis giant, Bedrocan Canada.

That merger allowed the company to seize huge market segments which in turn gave shareholders huge returns when cannabis stocks began to run in 2018.

Creso’s hope is that they can leverage Bruce’s connections within the international cannabis industry to shape their long-term strategy, along with streamlining their corporate and operational initiatives.

A WORD FROM CRESO PHARMA

A director of Creso Pharma Miri Halperin Wernli said Bruce would bring a “wealth of invaluable knowledge” to their team, alongside a “deep network of cannabis industry contacts”.

“We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value.

“We look forward to providing further updates in the near term,”
Miri stated. 
  
Visit Creso Pharma's Website
(20min delay)
Last
20.3¢
Change
0.003(1.25%)
Mkt cap ! $220.4M
Open High Low Value Volume
20.0¢ 20.5¢ 20.0¢ $1.482M 7.245M

Buyers (Bids)

No. Vol. Price($)
66 3785203 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
20.5¢ 136035 5
View Market Depth
Last trade - 12.03pm 16/04/2021 (20 minute delay) ?
(live)
Last
20.5¢
  Change
0.003 ( 3.59 %)
Open High Low Volume
20.5¢ 20.5¢ 20.0¢ 2926651
Last updated 12.20pm 16/04/2021 (live) ?
CPH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.